Successful encorafenib desensitization in a patient with recurrent metastatic melanoma

Grace D. Cullen; Heidi D. Finnes; Svetomir N. Markovic; Gerald W. Volcheck

doi:10.1097/CMR.0000000000000757

Successful encorafenib desensitization in a patient with recurrent metastatic melanoma

Grace D. Cullen, Heidi D. Finnes, Svetomir N. Markovic, Gerald W. Volcheck

Hematology

Research output: Contribution to journal › Article › peer-review

Abstract

Type I hypersensitivity reactions (HSR) to dabrafenib are rare but have been previously described. We present a case where a 72-year-old woman with recurrent, metastatic BRAF-mutated melanoma developed a type I HSR to dabrafenib. We, therefore, developed a desensitization protocol with encorafenib, a similar class agent, to allow the patient to continue with treatment. Patients with a history of HSR to dabrafenib may be considered for encorafenib desensitization when other therapeutic options are limited.

Original language	English (US)
Pages (from-to)	402-404
Number of pages	3
Journal	Melanoma research
DOIs	https://doi.org/10.1097/CMR.0000000000000757
State	Accepted/In press - 2021

Keywords

B-raf (BRAF)
Dabrafenib
Hypersensitivity reaction

ASJC Scopus subject areas

Oncology
Dermatology
Cancer Research

Access to Document

10.1097/CMR.0000000000000757

Cite this

@article{63bd225014564c05ab177f62dd3fa76d,

title = "Successful encorafenib desensitization in a patient with recurrent metastatic melanoma",

abstract = "Type I hypersensitivity reactions (HSR) to dabrafenib are rare but have been previously described. We present a case where a 72-year-old woman with recurrent, metastatic BRAF-mutated melanoma developed a type I HSR to dabrafenib. We, therefore, developed a desensitization protocol with encorafenib, a similar class agent, to allow the patient to continue with treatment. Patients with a history of HSR to dabrafenib may be considered for encorafenib desensitization when other therapeutic options are limited. ",

keywords = "B-raf (BRAF), Dabrafenib, Hypersensitivity reaction",

author = "Cullen, {Grace D.} and Finnes, {Heidi D.} and Markovic, {Svetomir N.} and Volcheck, {Gerald W.}",

note = "Publisher Copyright: Copyright {\textcopyright} 2021 Wolters Kluwer Health, Inc.",

year = "2021",

doi = "10.1097/CMR.0000000000000757",

language = "English (US)",

pages = "402--404",

journal = "Melanoma Research",

issn = "0960-8931",

publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Successful encorafenib desensitization in a patient with recurrent metastatic melanoma

AU - Cullen, Grace D.

AU - Finnes, Heidi D.

AU - Markovic, Svetomir N.

AU - Volcheck, Gerald W.

PY - 2021

Y1 - 2021

N2 - Type I hypersensitivity reactions (HSR) to dabrafenib are rare but have been previously described. We present a case where a 72-year-old woman with recurrent, metastatic BRAF-mutated melanoma developed a type I HSR to dabrafenib. We, therefore, developed a desensitization protocol with encorafenib, a similar class agent, to allow the patient to continue with treatment. Patients with a history of HSR to dabrafenib may be considered for encorafenib desensitization when other therapeutic options are limited.

AB - Type I hypersensitivity reactions (HSR) to dabrafenib are rare but have been previously described. We present a case where a 72-year-old woman with recurrent, metastatic BRAF-mutated melanoma developed a type I HSR to dabrafenib. We, therefore, developed a desensitization protocol with encorafenib, a similar class agent, to allow the patient to continue with treatment. Patients with a history of HSR to dabrafenib may be considered for encorafenib desensitization when other therapeutic options are limited.

KW - B-raf (BRAF)

KW - Dabrafenib

KW - Hypersensitivity reaction

UR - http://www.scopus.com/inward/record.url?scp=85109382489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85109382489&partnerID=8YFLogxK

U2 - 10.1097/CMR.0000000000000757

DO - 10.1097/CMR.0000000000000757

M3 - Article

C2 - 34132225

AN - SCOPUS:85109382489

SN - 0960-8931

SP - 402

EP - 404

JO - Melanoma Research

JF - Melanoma Research

ER -

Successful encorafenib desensitization in a patient with recurrent metastatic melanoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this